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Abstract
Introduction. Lung cancer is a complex disease and 
requires a multidisciplinary approach to achieve the 
best results in treatment, to increase the survival 
rate while preserving the quality of life of the suf-
ferer. The nutritional status of the patient is an im-
portant factor affecting outcome and recovery from 
disease or injury. We question whether there is a 
link between nutritional status and malignant pain in 
lung cancer patients.
Aim. A prospective trial was conducted to determine 
the distribution of respondents by frequency of pain 
according to a validated Visual Analog Scale (VAS), 
distribution of respondents who reported reduced 
food intake and distribution of factors that have led 
to the reduced food intake.
Methods. A prospective trial was conducted at the 
Department for respiratory diseases Jordanovac, Uni-
versity Hospital Center Zagreb, Croatia, on a sample 
of patients with advanced non-small cell lung can-
cer to determine the frequency, characteristics and 
treatment of chronic malignant pain (N=76). These 
are the results from November 2013 to June 2014. 
For pain assessment, we used a validated VAS. For 
the identification of patients at risk of malnutrition 
we used Nutritional risk screening tool (NRS 2002). 
For a rough estimate of total body adiposity, we 
measured dermal thicknesses using a standard cal-
liper. Monitoring of patients was documented in the 
form of nursing documentation. A component of 
Initial Assessment and Monitoring  
of Nutritional Status and Malignant 
Pain in Lung Cancer Patients
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Cancer induces a disorder in cellular function. Thus, al-
tered cells acquire the characteristics of rapid growth 
and the ability to spread to surrounding tissues in 
the body. Cancer cells have evolved to be able to 
face several obstacles, and during this process, they 
have become extremely resilient. Factors that are dif-
ficult to control and are responsible for about 30% 
of all cancers are hereditary, environmental or viral. 
On the other hand, approximately 70% of cancers are 
caused by other factors that are directly related to 
lifestyles, such as smoking, physical inactivity, obe-
sity, dietary composition, and excessive alcohol and 
opiate consumption (4,7). The symptoms of a malig-
nant disease are often very nonspecific which is one 
of the reasons for late detection of cancer. Symp-
toms that occur in patients with lung cancer are dry 
irritating cough - 50 to 75%, dyspnea - 25 to 40%, 
chest pain - 20 to 40%, hemoptysis - 20 to 50% (8-
11), fatigue, weakness, hoarseness (12,13), pleural 
effusion - 10 to 15% (5,14), superior vena cava syn-
drome, paraneoplastic syndrome and metastasis (5). 
Haematological disorders are anaemia (haemoglobin 
≤12 g/dL), which is present in 40% of patients who 
are not therapeutically covered and in 80% of pa-
tients who received chemotherapy (15), leukocytosis 
which is present in 15% and is most commonly asso-
ciated with hypercalcemia which is considered a poor 
prognostic factor in survival (16,17). Thrombocytosis 
is present in 14% and is an independent predictor 
for decreased survival (18,19). The most common 
coagulation disorders present in patients with lung 
cancer are Trousseau’s syndrome, deep vein throm-
bosis, thromboembolism, disseminated intravascular 
coagulation, thrombotic microangiopathy and non-
thrombotic microangiopathy (5). Despite all these 
symptoms and concomitant conditions, it should be 
noted that one quarter of patients with lung cancer 
are asymptomatic (20) while symptoms such as loss 
of appetite and weight are not pathognomonic for 
lung cancer, therefore further diagnostic testing is 
needed to detect the disease (8-10). 
Patients with lung cancer face several symptoms and 
side effects that interfere with their daily activities. 
Side effects negatively affect a patient’s quality of 
life during and after oncology treatment (6) and we 
divide them into those related to the disease itself 
and those that are the result of specific oncological 
treatment. Side effects associated with the disease 
are fatigue, dyspnea, difficulty swallowing, hemop-
tysis, pain and cancer anorexia/cachexia. Side effects 
nursing documentation was designed to monitor the 
nutritional status of cancer patients and has been 
implemented at the Department for respiratory dis-
eases Jordanovac as required documentation. The 
component included collecting the following data: 
the stage and type of cancer and treatment, demo-
graphic characteristics, age, gender, vital signs, body 
weight and height, body mass index (BMI), subjective 
symptoms such as pain, fatigue and nausea, reduc-
tion ad rezones of food consumption. 
Results. During the study 417 measurements were 
made: 1) 32,1% of patients reported reduced food in-
take, and 67,9% of respondents indicated that have 
not reduced their regular diet; 2) as a reason for the 
reduced food intake 37,7% respondents stated loss 
of appetite, 31,2% fatigue and 24,6% pain; 3) 59,5% 
subjects mainly reported absence of pain, while none 
of the respondents reported the existence of the 
highest degree of pain.
Conclusion. By regular monitoring of the intensity 
of the pain we achieved good control in malignant 
pain management, which is an important data in the 
assessment of nutritional status. The fact is that 
poorly controlled pain is present in 24% of patients 
and has been the reason for the reduced food intake.
Introduction
According to the Croatian Cancer Registry, in 2017, 
2,232 men and 1,003 women were diagnosed with 
tracheal, bronchial and lung cancer, with the second 
being most common cancer in men (17%) and the 
third in women (9%) (1). Worldwide, in 2012 lung 
cancer occurred in approximately 1.8 million patients 
and caused an estimated 1.6 million deaths (2). The 
incidence increased over the years and in 2018 lung 
cancer occurred in approximately 2.1 million patients 
and caused an estimated 1.7 million deaths (2,3). 
Lung cancer refers to malignant diseases that origi-
nate from the airways and lung parenchyma. Based 
on the origin of the cell it is divided into small cell 
lung cancer (SCLC) and non-small cell lung cancer 
(NSCLC). In patients with lung cancer, it is necessary 
to define the cell type before starting with specific 
and personalized oncological treatment (4-6).
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are at an increased risk of food aspiration. The 
initial management dysphagia is an immediate 
change in diet and food consistency (28).
Anorexia/cachexia
Anorexia and weight loss are common in patients 
with lung cancer, they can occur due to the under-
lying disease or specific oncological treatment (6). 
Anorexia or loss of appetite may be associated with 
a tumour-host interaction, loss of taste sensation, 
dysphagia, stomatitis, gastroparesis, nausea, vomit-
ing, distal intestinal obstruction syndrome, specific 
oncological treatment, pain and depression. Anorexia 
leads to reduced food intake, resulting in weight loss 
which is a bad prognostic sign (6,28). 
Cachexia is a hypercatabolic condition defined by 
accelerated skeletal muscle loss in the context of a 
chronic inflammatory response that occurs in cancer 
patients (28). Cachexia consists of weight loss of 
≥10% over 6 months, manifested by asthenia and 
general weakness, changes in physical appearance 
and mental stress (31-35). Weight loss in patients 
with cachexia is not only caused by reduced food 
intake but is also caused by metabolic abnormali-
ties. Metabolic abnormalities lead to an increase in 
basal energy that results in weight loss in skeletal 
muscle. Cachexia is defined using a three-stage sys-
tem: pre-cachexia, cachexia, and refractory cachexia 
(34,36,37). 
Estimation of loss of body weight is often neglected 
in patients who are obese, edematous or with the 
expansion of tumours (34,36,38). According to some 
studies, cachexia occurs in 50% of cancer patients 
(regardless of the stage of the disease), and 80% of 
patients with an advanced malignant disease (34). 
The importance of these data is significant because 
a loss of only 5% of body weight can significantly 
worsen the prognosis of cancer patients and short-
en overall survival (39). Despite these findings, the 
problem of malnutrition in hospitals remains largely 
unrecognized (40). From all the above, it is important 
to assess and regularly monitor the nutritional status 
of patients, monitor and record side effects and act 
accordingly. Accordingly, to the importance of these 
data at Department for respiratory diseases Jordano-
vac, UHC Zareb, component of nursing documenta-
tion was designed and implemented as mandatory 
nursing documentation for assessment and regularly 
monitoring the general condition and nutritional sta-
associated with specific oncological treatment are 
nausea, vomiting, diarrhoea, constipation, alopecia, 
change in taste or smell, esophagitis, fatigue, anae-
mia, leukopenia, thrombocytopenia, infections, pain 
and thigh numbness, skin changes, pain, anorexia/
cachexia (6). The prognosis of survival in patients 
with NSCLC decreases with the progression of the 
underlying disease (6) factors that predict mortality 
include weight loss and Eastern Cooperative Oncol-
ogy Group (ECOG) Performance Status. Decreased ap-
petite is an indicator of weight loss and a negative 
predictor of survival in lung cancer patients (21-26). 
Factors that lead to reduced intake of nutrients in 
cancer patients
• Pain is the most stressful and worrying symp-
tom for patients and their families. 80% of can-
cer patients are affected by pain. Fortunately, 
well-controlled pain is possible in most cases. 
Opioids are the leading therapy for moderate 
to severe pain and it is very important to pro-
vide adequate psychosocial support (27).
• Dyspnea is a common symptom of lung cancer 
and intrathoracic metastatic disease (28).
• Insomnia is a common and stressful symptom 
in terminally ill patients. It affects quality of 
life and may increase the intensity of other 
symptoms such as pain, anxiety or delirium 
(28).
• Fatigue (asthenia, weakness) is the most com-
mon and typical multidimensional symptom in 
lung cancer patients that affects the quality 
of life. In most cases, fatigue is a symptom not 
promptly diagnosed and treated (28).
• Nausea and/or vomiting are present in most 
patients due to metabolic abnormalities, opi-
oid administration, pharmacological therapy 
and brain metastasis (28).
• Xerostomia, also known as dry mouth, has 
been described as a feeling of dryness in the 
mouth that makes it difficult to chew and 
swallow (29), which may be associated with: 
radiotherapy, chemotherapy, surgery (espe-
cially head and neck), drugs (anticholinergics, 
antidepressants, opioids, anxiolytics, antihis-
tamines, beta-blockers), dehydration and oral 
infection (30).
• Radiation-induced dysphagia is a common 
symptom in cancer patients undergoing up-
per esophageal radiotherapy. These patients 
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The component was created by the author of this 
paper and is based on real needs as well as experi-
ences in literature. The component aimed to design 
monitoring of the general and nutritional status of 
oncology patients to monitor and possibly predict 
the patient’s future condition, improve or deteriorate 
concerning nutritional status, and the possibility of 
taking the necessary preventive and curative meas-
ures (41).
The component included the collection of the follow-
ing data: data on disease stage and cancer type, data 
on the type and stage of treatment - treatment line 
and cycles, demographic characteristics of subjects 
(age and gender), skinfold thickness, standardized 
screening using Nutritional Risk Screening 2002 
questionnaire (42,43), vital signs - blood pressure 
(mm Hg), heart rate and number of respirations/
minutes, body weight in kg, body height in cm, body 
mass index (BMI) - calculated in the following equa-
tion: BMI = bodyweight ÷ [height]², i.e. corrected for 
age = (m/h2) - (a - 30)/10 ; 30<a<75. where a is = age. 
Furthermore, for comparison, we categorize levels of 
malnutrition based on BMI: malnutrition (category 1) 
BMI <18.5, ideal weight (category 2) BMI 18.5 – 24.9, 
overweight (category 3) BMI 25.0 – 29.9, obesity 
grade 1 (category 4) BMI 30.0 – 34.9. Subjective as-
sessment of the patient identified conditions of fa-
tigue and nausea, food intake and further analyzed 
the reasons for reduced nutrition (if it occurred). A 
subjective assessment of nausea and vomiting was 
followed for the first five days after chemotherapy. A 
visual analogue scale (VAS) was used to assess pain. 
The VAS scale has a range of 0–10, where the lowest 
value of 0 indicates no pain, and the highest value of 
10 indicates unbearable pain (41,44,45).
The survey took place every time the respondents 
arrived for therapy. The time interval between thera-
pies was three weeks. Each time the respondents 
arrived, a new list of assessments and monitoring 
was opened. Weight measurement was always car-
ried out using the same scale. The respondents were 
in their clothes when weighed, without a jacket or 
shoes. Skinfold thickness was measured with an 
electronic calliper (Finesse), at the right upper arm.
tus patients with lung cancer. Data from the compo-
nent of nursing documentation are analyzed in this 
paper (41).
The research aimed to determine the distribution 
of respondents by the frequency of the presence of 
pain, the distribution of subjects in which reduced 
food intake was present and to determine the rea-
sons that have led to reduced food intake. The pur-
pose of this paper was to encourage research which 
would lead to timely intervention in everyday clinical 
practice when risks of malnutrition occur. Through 
the observation of malnutrition, we can better as-
sess the possible outcome of therapy and the course 
of the disease.
Methods
A prospective trial was conducted at the Department 
for respiratory diseases Jordanovac, University Hos-
pital Center Zagreb, Croatia, in the period from No-
vember 2013 to June 2014, on a sample of patients 
with advanced non-small cell lung cancer. During this 
period patients received cancer treatment (chemo-
therapy) and nutrition support according to current 
Croatian guidelines (N=76). This sample represents a 
deliberately selected sample that corresponds to the 
patient population of the clinic.
For assessment and regulatory monitoring general 
condition and nutrition status in these patients, we 
used the mandatory part of the nursing documenta-
tion (41). Patients were informed that their data will 
be used in an anonymized form and will only be used 
for this paper. Patients were informed about the pur-
pose of the component of nursing documentation and 
their rights. The response rate of patients who came 
to therapy was 100%. Interviewing at the depart-
ment was conducted by two specially trained nurses 
who were responsible for administering therapy as 
well, thus reducing variability in data collection. Sam-
ple control and data collection were performed on 
all patients with advanced non-small cell lung can-
cer included in the study by the authorized specially 
trained nurses. The average duration of completing 
the questionnaire was between 10 and 15 minutes.
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ments during the study was in the fourth line of 
patient treatment (1.7%). The percentage of meas-
urements observed during reevaluation between 
treatment lines was 15.9%. The central value is 1 
while the mode is also 1.
When examining body mass index, we ranked pa-
tients by category at each measurement. From 
overall 417 measurements, 44.8% of patients had 
an ideal weight, 37.4% were overweight and 14.6% 
obese. To assess the nutritional status of healthy in-
dividuals the calculation of BMI is usually used. This 
is a relatively precise measure of body mass and is, 
therefore, most commonly used for health risk as-
sessment (Table 1).






F 0% 50% 50%
M 3.4% 44.8% 51.7%
In the study, we conducted more detailed descriptive 
tests and compared the relationship of nutritional 
status with other measured and collected parame-
ters. In each table, we have paired the nutritional sta-
tus with another parameter to take a more detailed 
look at the distribution schedule (Table 2).
Table 2. Nutritional status/BMI
BMI
Nutritional status
Severe risk Mild malnutrition
Malnutrition 8.3% 0%




62.8% of subjects of ideal body weight were at se-
vere risk of malnutrition and 65.9% of overweight 
subjects had mild malnutrition.
According to the data obtained, 3.1% of patients were 
malnourished at some point of the study, while none of 
the patients was in the category of severe obesity by 
body weight index. The average body mass index of the 
Ethics
The component of nursing documentation was intro-
duced as mandatory nursing documentation at the 
Department for respiratory diseases Jordanovac, Uni-
versity Hospital Center Zagreb, Croatia, in 2013. The 
Croatian Chamber for nurses as a regulatory body 
approved a component of nursing documentation, 
the implementation and analysis of the documenta-
tion was carried out according to the highest ethical 
standards of the nursing profession. The Ethics Com-
mittee of the Croatian Chamber of Nurses approved 
the study on the basis that it was a non-interven-
tional study. The data were collected as part of the 
usual nursing history, there was no need for patients 
to sign a separate informed consent to participate in 
the study.
Statistics
The data collected were analyzed by statistical suite 
Statistica 16.0, licensed at the University Computing 
Center (SRCE, site:0082452005), and Microsoft Ex-
cel with Office Version 2010. 
Differences between studied subgroups (women and 
men, lines of therapy, risks of malnutrition) were ana-
lyzed using descriptive statistic (frequency distribu-
tions and contingency tables), while the correlations 
were analyzed using bivariate (Pearson) correlation 
analysis.
Results 
A total of 76 lung cancer patients participated in 
the study, of which 58 (76.3%) men and 18 (23.7%) 
women. 76 subjects had an average of 5 visits to our 
department, the total number of measurements was 
417. The age range of subjects was between 47 and 
89 years of age, with an average age of 65 years. 
The central value or median is 65, while the most 
common value or mode is 62. 
Using descriptive analysis, we confirmed that the 
highest percentage of measurements of subjects 
in the study was during the first line of treatment 
(59.3%) while the lowest percentage of measure-
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*total number of measurements
Throughout the study, lung cancer patients on a scale 
of 0 to 10 (where number 0 indicates a pain-free 
condition and number ten the highest possible level 
of pain) indicated the current feeling of pain at each 
measurement. During the study, most of the subjects 
reported no existence of pain (59.5%), while no sub-
ject reported the highest level of pain (Table 5).
Table 5. Distribution of pain frequency













Using a bivarious correlation test, we examined the 
association between the nutritional status of lung 
cancer patients and the loss of their body mass dur-
ing the study. All tests were carried out at the risk 
patient corresponds to the category of ideal weight. The 
median body mass index is 25.24, which corresponds to 
excessive weight, while the mode is 20.30. 
When included in the study, all subjects were meas-
ured, the subject with the lowest body weight 
weighed 47 kilograms while the subjects with the 
highest weight weighed 123 kilograms. The average 
weight of the subjects was 76.27 kilograms. The cen-
tral value was 74, while the mode was 81, which is 
the most common recorded weight of subjects (4.3%).
In the first measurement, weight gain was only 9%, 
while the cumulative measurement increases the 
proportion of subjects who gained weight to 27%. A 
positive shift is seen in each category except in the 
category of subjects who in the first measurement 
had a loss greater than 10 kg (Table 3).
By analyzing the nutritional status of patients as op-
posed to body mass index, values were obtained in 
only two categories (mild malnutrition and severe 
risk) and 62.6% of subjects were in the category of 
mild malnutrition, in the severe risk category, 37.4% 
of subjects, while none were in the risk-free catego-
ry. 67.9% of subjects who had a reduced diet during 
the study were at severe risk of malnutrition. In the 
same way, subjects who did not report reduced food 
intake during the study were more slightly malnour-
ished at 89.3%.
82.1% of subjects (45-69 years of age) reported de-
creased food intake compared to 66.7% of subjects 
(70+ years of age). The study carried out 417 meas-
urements, regardless of the age group, 32.1% report-
ed reduced food intake and 67.9% of respondents said 
they did not reduce food intake. In the study group 
who reported that they had reduced food intake, 134 
measurements were performed, the most common 
reasons for reduced food intake are listed in Table 4.
Table 3. Age/Weight loss (first and cumulative measurement)
Age
Weight loss/weight gain (kg)
From -30 to -10 From -9 to -1 0 From +1 to +6
45 - 69 12.7% / 21.7% 56.3% / 40.1% 21.8% / 10.9% 9% / 27.1%
70+ 19.1% / 33.5% 47.7% / 24% 28.6% / 19.0% 4.8% / 23.8%
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Discussion  
Lung cancer has the highest mortality rate in the 
world (46), with a poor survival prognosis, 16% sur-
vival in 5 years (47,48). In Croatia, the incidence by 
type of cancer, the cancer of trachea, bronchial and 
lungs is in the second most common type of cancer in 
men and the third in women. According to the latest 
data from the Cancer Registry in 2017, 3235 (2232 
men/1003 women) patients with tracheal, bronchial 
and lung cancer were diagnosed (1).
It is interesting to keep track of how the number of 
women suffering from bronchial, tracheal and lung 
cancers is growing worldwide, and we are unfortu-
nately seeing this trend in the Republic of Croatia. In 
2013, according to the data from the Department for 
respiratory diseases Jordanovac, University Hospital 
Center Rebro, Zagreb, Croatia, we also recorded an 
increase in the proportion of women suffering from 
tracheal, bronchial and lung cancer the proportion 
of men 75%, and women 25%, while in 2009, the 
proportion of men was 77% and women 23%. The 
gender distribution of the sample coincides with the 
distribution of patients by gender who underwent 
oncological treatment at the Department for respira-
tory diseases Jordanovac, University Hospital Center 
Rebro, Zagreb, Croatia, in 2013.
The calculation of BMI is used to assess the nutri-
tional status of healthy individuals. This is a relatively 
precise measure of body mass and is, therefore, most 
commonly used to assess health risks. In our survey, 
44.8% of respondents had an ideal body mass and 
52% higher than ideal. By correlation between body 
mass index and nutritional status, 62.8% of subjects 
of ideal body weight had a severe risk of malnutrition 
and 65.9% of overweight subjects were mildly mal-
nourished. The conclusion is that BMI is not neces-
sarily relevant or sufficient to assess the nutritional 
status of lung cancer patients, which corresponds to 
the opinion of other authors who state that in the 
case of cancer patients BMI is not a valid indicator for 
assessing nutritional status. According to the results 
obtained by our study, BMI was not a relevant indi-
cator for assessing nutritional status in lung cancer 
patients older than 65 (49).
Weight loss is common in oncology patients, it may 
be caused by various factors such as mucositis, dys-
level of 5% (p<.05). We found that there was a high 
interconnection between the subjects’ weight loss 
and their nutritional status (r=0.464; p<0.000). 
Such a high association was to be expected given 
that weight loss itself is indicative of the degree 
of nutritional status. We also checked the asso-
ciation between the subjects’ weight loss and lack 
of appetite. We found that there was a relatively 
high negative association between the two factors 
(r=-0.370; p<0.001). The negative association, in 
this case, indicates that if there is reduced food in-
take, there is also weight loss. In the same way, if 
there is no reduced food intake, there is less weight 
loss. Through further testing, we looked at the pos-
sible link between the lines of treatment that lung 
cancer patients underwent through the research pe-
riod and the possible lack of appetite. We found that 
there was no statistically significant association be-
tween treatment lines and the occurrence of the lack 
of appetite. By testing the association between the 
number of treatment cycles and reduced food intake 
of subjects, we did not find a significant statistical 
correlation and had to determine that the two param-
eters were not interdependent. Among other things, 
we were interested in whether there was a statis-
tically significant association between the subjects’ 
body mass index and their nutritional status. The 
results show that there is a relatively high associa-
tion between these two factors (r=0.376; p<0.000). 
These results were expected since the body mass in-
dex directly affected the patients’ nutritional status. 
By testing the association between the nutritional 
status of subjects and the number of cycles of chem-
otherapy in treatment during the study, it was shown 
that there was a weak correlation between these 
two factors (r=0.098; p<0.046). Even though the 
association is weak the findings nonetheless show 
how nutritional status and treatment cycle are inter-
dependent. By looking at the parameters collected, 
we also tested the association between nutritional 
status and the thickness of the skin folds and found 
that there was a positive high association between 
the two parameters (r=0.410; p<0.000) - the higher 
the thickness of the skin folds, the higher the degree 
of nutritional status.
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Malnutrition is defined as the nutritional status in 
which energy, proteins or other nutritional ingredi-
ents are in deficit, their deficiency leads to visible 
and measurable adverse side effects in tissue, func-
tion and clinical outcomes. Malnutrition occurs in 40 
to 80% lung cancer patients (50,53-55), unrelated 
to the cause leads to a decrease in quality of life 
(50,56-59), lower response to chemotherapy treat-
ment (39,56,60), increased toxicity related to the 
chemotherapy treatment (61-63), reduces the ben-
efits of pharmacological therapy (60,61), prolongs 
postoperative recovery (64,65), reduces survival 
(39,56,66) and it is the leading cause of mortality in 
the advanced stage of the disease (50,53-55). 
Anorexia has been linked to reduced food intake, 
weight loss and can lead to cancer anorexia-cachexia 
syndrome (CACS) (67). CACS was identified as a risk 
factor for reduced quality of life and poorer survival 
prognosis. Most lung cancer patients will develop 
CACS, for this reason, it is extremely important to 
promptly implement early interventions in patients 
with cachexia. Early nutritional and pharmacological 
interventions as well encouragement on physical ac-
tivity are used in the prevention of the occurrence of 
CACS (68,69). Pharmacological interventions in CACS 
successfully reduce or resolve a large proportion of 
symptoms in lung cancer patients (pain, dyspnea, 
nausea/vomiting, fatigue) (28), improve appetite, 
reduce systemic inflammation and improve anabolic 
metabolism (69-72). 
Pain is a common problem that significantly affects 
the reduction in food intake. ECOG Performance Sta-
tus, weight loss, dyspnea, fatigue and pain are signif-
icant prognostic indicators, associated with reduced 
quality of life and with a lower survival prognosis 
(73,74). A prospective study was conducted on a 
sample of 301 patients with non-small cell lung can-
cer to determine the frequency, characteristics and 
treatment of chronic malignant pain. The intensity of 
pain is determined by a visual analogue scale (VAS). 
Most patients experienced moderate and high-inten-
sity pain (47% and 26%), and only 5% of patients had 
sufficient analgesic therapy, while more than 90% 
of patients were treated outside the recommended 
therapeutic guidelines (75). 
In our sample by examining the pain frequency distri-
bution of subjects, according to the visual analogue 
scale mild pain (VAS<3) was experienced by 10.3% of 
subjects, mild to medium pain (VAS 3-6) by 24.3% of 
subjects, and severe pain (VAS more than 6) by 6% of 
phagia, loss of appetite and metabolic abnormalities 
(50). During our study on weight loss or gain, a posi-
tive shift in the course of treatment was observed in 
most subjects, except for subjects who had already 
had a drop in body weight greater than 10 kilograms 
at the first measurement. In the age group between 
45 and 69 years, weight loss greater than 10 kilo-
grams was observed in 12.7% of subjects at the first 
measurement, by cumulative measurement during 
treatment it increased to 21.7%. In the age group 
70+, 19.1% of subjects had weight loss at the first 
measurement, by cumulative measurement during 
treatment it increased to 33.5%. Age-group differ-
ences are not surprising. With age, metabolic, physio-
logical and biochemical processes change, and these 
changes have an adverse effect on nutritional status 
in older people. The sharpness of taste, smell, loss of 
teeth, and thus decrease the possibility of enjoying 
food. With ageing the body’s composition changes, 
muscle mass decreases and metabolism slows down 
(49). This data indicates the importance of timely 
nutritional support to avoid irreversible cachexia. It 
is assumed that adequate caloric intake by enteral 
or parenteral route would be the optimal approach in 
addressing weight loss in oncology patients. In the 
terminal stages of lung cancer, the nutritional sup-
plement has a non-beneficial effect and it is not rec-
ommended (50-52).
During our study, collected data shows that weight 
loss less than 10 kilograms at the first measurement 
and by cumulative measurements record a decrease 
in the proportion of weight loss during treatment. It 
was interesting to note that a significant decrease 
in body weight precedes disease progression and 
weight loss can be seen in part as a possible diag-
nostic parameter in the monitoring of lung cancer 
patients. Due to the small number of respondents 
in this sample, we did not determine the statistical 
significance of this occurrence. Weight loss is an im-
portant criterion for diagnosing pre-cachexia and ca-
chexia and is a negative prognostic survival sign for 
cancer patients. Dewys et al. conducted a study on a 
sample of 3,047 lung cancer patients to determine 
the association between weight loss and chemo-
therapy treatment. They found that weight loss was 
correlated with decreased general patient status, 
reduced median survival, reduced rate of chemo-
therapy response, and the frequency of weight loss 
increased by increasing the number of metastatic 
changes (39).
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Conclusion
Initial assessment and monitoring of nutritional status 
must be a mandatory and inseparable part of the care 
of lung cancer patients. The component of nursing 
documentation (41) contains all parameters relevant 
for assessing and monitoring the nutritional status of 
lung cancer patients. By systematically monitoring the 
nutritional status of patients, we can monitor and ana-
lyze the frequency and reasons for the occurrence of 
individual symptoms, enabling their timely detection 
and adequate timely intervention. 
Based on the research and the results obtained, the 
following conclusions can be drawn: body mass index 
is associated with the risk of malnutrition but is not a 
sufficient indicator for assessing the nutritional sta-
tus of cancer patients and the elderly. Although we 
expected an association between the stage of chem-
otherapy and reduced food intake, no association 
between the number of oncology cycles and the oc-
currence of reduced food intake was demonstrated. 
There is a poor correlation between nutritional status 
and treatment lines, which can be explained by the 
sample size and individual characteristics of the sub-
jects. Initial weight loss greater than 10 kilograms in 
both age categories, and in particularly the category 
70+, was associated with a reduced response to nu-
tritional support, and during differentiated treatment 
weight loss continued. By continuous monitoring of 
pain intensity good control of malignant pain in the 
study population was achieved, which is an impor-
tant data in the assessment of nutritional status 
since poorly controlled pain in 24% of subjects is the 
reason for reduced food intake. 
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subjects. No pain was reported in 59.5% of subjects, 
and no subjects indicated pain intensity VAS 10. A to-
tal of 24.6% of subjects reported pain as a reason for 
reduced food intake, which corresponds to the propor-
tion of subjects who had inadequately controlled pain, 
VAS greater than 5. Comparatively to the above-men-
tioned study, we see a significant shift in the control of 
malignant pain in the study population.
Nutritional deficiency and the presence of pain are 
common in lung cancer patients, especially in the ad-
vanced-stage disease. Chabowski et al. conducted a 
study on a sample of 257 lung cancer patients to de-
termine the association between pain perception, nu-
tritional status and level of anxiety, depression. 23% 
of patients were malnourished, 33% at risk of malnu-
trition and 44% with a normal nutritional status. 65% 
of subjects had symptoms of depression and 65% of 
anxiety. A significant negative correlation was present 
between nutritional status and pain as well as be-
tween nutritional status, anxiety and depression (76). 
The prevalence of nutritional status disorders, the 
intensity of somatic symptoms and psychological 
stress are common in lung cancer patients. The indi-
cation for early intervention measures (psychological 
and pharmacological) is extremely important in lung 
cancer patients who have an increased risk of malnu-
trition, significant levels of depression, anxiety and 
pain (76). Turcott et al. documented a link between 
well-controlled pain with opioids and improvements 
in nutritional status. Besides, with well-controlled 
pain, cancer patients had increased food intake, a 
better quality of life, emotional and social function-
ing, better pain control and sleep. With adequate 
opioid use, anorexia is less common in lung cancer 
patients compared to patients in the control group 
without opioid use (72). 
The nutritional status disorder leads to malnutrition, 
which is common in oncology patients and the lead-
ing cause of a decrease in quality of life and surviv-
al. We assumed at the beginning of the study that 
the leading causes of food intake reduction would 
be the most frequent side effects of chemotherapy 
treatments such as nausea and vomiting, but after 
analyzing the data we noticed that pain was a more 
common cause of food intake reduction. Based on 
the data obtained from our sample compared to the 
other studies in the discussion, we can conclude that 
assessment and well-controlled pain is necessary for 
maintaining adequate nutritional status in lung can-
cer patients.
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kumentacija. Sastavnica je obuhvatila prikupljanje 
sljedećih podataka: stadij bolesti i tip karcinoma, tip 
i stadij liječenja, demografske karakteristike ispi-
tanika, debljina kožnog nabora, standardizirani upit-
nik o pothranjenosti Nutritional NRS 20021, vitalni 
znakovi, tjelesna težina, tjelesna visina, indeks tjele-
sne mase, subjektivna procjena pacijenta; bol, umor i 
mučnina, razlozi smanjene prehrane.
Rezultati. Tijekom provedenog istraživanja izvede-
no je 417 mjerenja: 1) 32,1 % ispitanika prijavilo je 
smanjeni unos hrane, a 67,9  % istaknulo kako nisu 
smanjivali redovitu prehranu; 2)  najučestaliji uzroci 
smanjenog unosa hrane u ispitanika su bili nedostatak 
apetita (37,7 %), prisutnost umora/slabosti (31,2 %) i 
prisutnosti boli (24,6 %); 3) 59,5 % ispitanika prijavilo 
je nepostojanje boli, dok nijedan ispitanik nije prijavio 
postojanje najvećeg stupnja boli.
Zaključak. Redovitim praćenjem intenziteta boli os-
tvarena je dobra kontrola maligne boli kod ispitivane 
populacije, što je važan podatak kod procjene nutri-
tivnog statusa. Činjenica je da je loše kontrolirana bol 
u 24 % ispitanika razlog smanjenog unosa hrane.
Ključne riječi: rak pluća, nutritivni status, bol, sastavnica 
sestrinske liste
Sažetak
Uvod. Rak pluća jest kompleksna bolest i zahtijeva 
multidisciplinarni pristup kako bi se postigli što bolji 
rezultati u liječenju i povećala stopa preživljavanja 
uz istodobno očuvanje kvalitete života oboljelog. 
Nutritivni status bolesnika pokazao se važnim čim-
benikom koji utječe na ishod i oporavak od bolesti ili 
ozljede. Postavljamo pitanje postoji li poveznica iz-
među nutritivnog statusa i maligne boli u bolesnika 
s rakom pluća.
Cilj. Provedeno je prospektivno istraživanje kako bi 
se utvrdila raspodjela ispitanika prema učestalosti 
bolova prema validiranoj vizualnoj analognoj skali 
(VAS), raspodjela ispitanika koji su prijavili smanjeni 
unos hrane i raspodjela čimbenika koji su doveli do 
smanjenog unosa hrane.
Metode. Istraživanje je provedeno na Zavodu za 
tumore pluća i sredoprsja Klinike za plućne bolesti 
Jordanovac Kliničkoga bolničkog centra Zagreb, na 
uzorku bolesnika s uznapredovalim rakom pluća ne-
malih stanica (N = 76). u periodu od studenoga 2013. 
do lipnja  2014. Za procjenu boli primijenjen je va-
lidirani VAS. Za identifikaciju pacijenata s rizikom 
od pothranjenosti primijenjen je alat za provjeru 
prehrambenih rizika (NRS 2002). Za grubu procjenu 
količine masnog tkiva koristili smo se kaliperom. 
Praćenje bolesnika dokumentirano je u obliku sestrin-
ske dokumentacije. Sastavnica sestrinske dokument-
acije osmišljena je za praćenje prehrambenog stanja 
oboljelih od karcinoma i implementirana je na Odjelu 
za respiratorne bolesti Jordanovac kao potrebna do-
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